The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Design and rationale of a first-in-human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible (irrev), pan-FGFR inhibitor (FGFRi), in adult patients with solid tumors harboring FGFR2 and/or FGFR3 gene alterations (NCT05242822).
 
Lipika Goyal
Consulting or Advisory Role - Agios; Alentis Therapeutics; AstraZeneca; Debiopharm Group; Exelixis; Genentech; H3 Biomedicine; Incyte; Klus Pharma; QED Therapeutics; Sirtex Medical; Taiho Pharmaceutical
(OPTIONAL) Uncompensated Relationships - Agios; Debiopharm Group; Merck; Taiho Pharmaceutical
 
Cesar Augusto Perez
Consulting or Advisory Role - Regeneron
Research Funding - Alkermes (Inst); Artios (Inst); Kinnate Biopharma (Inst); Kura Oncology (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Ribon Therapeutics (Inst)
 
Shumei Kato
Honoraria - Roche
Consulting or Advisory Role - Foundation Medicine; Pfizer/EMD Serono
Speakers' Bureau - Bayer
Research Funding - ACT Genomics; Konica Minolta; OmniSeq; Sysmex
 
Manish Sharma
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Alexion Pharmaceuticals; Amgen; Biogen; Bristol-Myers Squibb; Lilly; Medtronic; Merck; Pfizer; Regeneron
Research Funding - Abbvie (Inst); Agenus (Inst); Alexo Therapeutics (Inst); Alpine Immune Sciences (Inst); Arrys Therapeutics (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Compugen (Inst); Constellation Pharmaceuticals (Inst); Coordination Pharmaceuticals (Inst); CytomX Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Epizyme (Inst); Exelixis (Inst); Forty Seven (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline/Tesaro (Inst); Helsinn Therapeutics (Inst); Ikena Oncology (Inst); InhibRx (Inst); Innovent Biologics (Inst); Jounce Therapeutics (Inst); KLUS Pharma (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); NGM Biopharmaceuticals (Inst); Odonate Therapeutics (Inst); Onconova Therapeutics (Inst); Pfizer (Inst); PureTech (Inst); Regeneron (Inst); Samumed (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Shattuck Labs (Inst); Symphogen (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Treadwell Therapeutics (Inst)
 
Benjamin Garmezy
(OPTIONAL) Uncompensated Relationships - AVEO (Inst)
 
Ken Kobayashi
Employment - Daiichi-Sankyo; Kinnate Biopharma; Pfizer
Stock and Other Ownership Interests - Daiichi Sankyo; Kinnate Biopharma; Pfizer
Patents, Royalties, Other Intellectual Property - MOU for KIN-3248
 
Aleksandra Franovic
Employment - Bristol-Myers Squibb; Celgene; Kinnate Biopharma
Stock and Other Ownership Interests - Bristol-Myers Squibb; Guardant Health; Kinnate Biopharma
 
Betty Tam
Employment - Biomerieux (I); Bristol-Myers Squibb/Celgene; Kinnate Biopharma
Stock and Other Ownership Interests - Biomerieux (I); Kinnate Biopharma
 
Cynthia Voong
Employment - Kinnate Biopharma
Stock and Other Ownership Interests - Kinnate Biopharma